Earnings summaries and quarterly performance for MoonLake Immunotherapeutics.
Executive leadership at MoonLake Immunotherapeutics.
Board of directors at MoonLake Immunotherapeutics.
Research analysts covering MoonLake Immunotherapeutics.
Recent press releases and 8-K filings for MLTX.
MoonLake Immunotherapeutics Faces Securities Class Action Lawsuit
MLTX
Legal Proceedings
Demand Weakening
- Hagens Berman has filed a securities class action lawsuit against MoonLake Immunotherapeutics (MLTX), alleging the company concealed material adverse facts regarding the clinical performance of its drug SLK and its ability to differentiate from competitors like BIMZELX.
- The lawsuit claims MoonLake misrepresented that SLK's distinct Nanobody structure would provide superior clinical efficacy, failing to disclose that it did not confer a meaningful clinical advantage in the Phase 3 VELA trials.
- As a result of these alleged undisclosed trial flaws, MLTX's stock experienced a 90% loss, falling from $61.99 to $6.24 on September 29, 2025.
- Investors who purchased MLTX shares during the Class Period, from March 10, 2024, through September 29, 2025, and suffered substantial losses, are encouraged to contact Hagens Berman, with the lead plaintiff deadline set for December 15, 2025.
1 day ago
MoonLake Immunotherapeutics Faces Securities Class Action Lawsuit
MLTX
Legal Proceedings
Demand Weakening
- Hagens Berman is investigating MoonLake Immunotherapeutics (MLTX) regarding alleged undisclosed facts about SLK's clinical performance and its ability to differentiate from competitors like BIMZELX.
- The lawsuit focuses on an alleged gap between MoonLake's optimistic public statements and the undisclosed reality of SLK's performance in the Phase 3 VELA trials.
- Allegations include the company's failure to disclose that SLK and BIMZELX share the same molecular targets (interleukin-17, or IL-17), and misrepresenting that SLK's Nanobody structure would provide superior clinical efficacy.
- MLTX stock experienced a 90% loss, falling from $61.99 to $6.24 on September 29, 2025.
- The deadline for investors to move the Court for appointment as lead plaintiff in the securities class action lawsuit is December 15, 2025.
3 days ago
MoonLake Immunotherapeutics' Stock Crashes and Faces Lawsuit
MLTX
Legal Proceedings
Profit Warning
- MoonLake Immunotherapeutics' stock crashed nearly 90% in a single day, falling from $61.99 to $6.24, following the release of disappointing Phase 3 trial results for its lead and only drug candidate, sonelokimab (SLK).
- The VELA-2 Phase 3 trial failed to meet its primary endpoint, and the efficacy results for SLK were noted to be substantially lower than those previously achieved by the competitor drug, BIMZELX.
- A securities fraud class action lawsuit has been filed, alleging MoonLake made materially false and misleading statements to investors about SLK's clinical prospects and exaggerated its benefits over competitors.
- The lawsuit's Class Period is from March 10, 2024, to September 29, 2025, with a Lead Plaintiff Deadline of December 15, 2025.
6 days ago
MoonLake Immunotherapeutics' Stock Crashes 90% Following Disappointing Phase 3 Trial Results, Triggers Lawsuit
MLTX
Legal Proceedings
Profit Warning
- MoonLake Immunotherapeutics' (MLTX) stock crashed nearly 90% on September 28, 2025, after its lead and only drug candidate, sonelokimab (SLK), reported disappointing Phase 3 trial results.
- The VELA-2 Phase 3 trial for SLK failed to meet its primary endpoint, and its efficacy results were substantially lower than those of a competitor drug, BIMZELX.
- A securities fraud class action lawsuit has been filed, alleging that MoonLake and certain executives made materially false and misleading statements about SLK's clinical prospects and exaggerated its benefits.
- The class period for the lawsuit is from March 10, 2024, to September 29, 2025, with a lead plaintiff deadline of December 15, 2025.
Nov 26, 2025, 1:50 PM
MoonLake Immunotherapeutics Faces Lawsuit After Disappointing Drug Trial Results
MLTX
Legal Proceedings
Profit Warning
- MoonLake Immunotherapeutics (MLTX) stock plummeted nearly 90% on September 28, 2025, following the release of disappointing Phase 3 trial results for its lead and only drug candidate, sonelokimab (SLK).
- The VELA Phase 3 trials for SLK, intended to treat moderate to severe hidradenitis suppurativa, included the VELA-2 trial which failed to meet its primary endpoint, and efficacy results were substantially lower than a competing drug, BIMZELX.
- A securities fraud class action lawsuit has been filed against MoonLake and certain executives, alleging they made materially false and misleading statements about SLK's clinical prospects and exaggerated its benefits.
- The stock price fell by $55.75 per share, from $61.99 to $6.24, in the trading day after the news.
Nov 25, 2025, 9:31 PM
MoonLake Immunotherapeutics' Stock Plummets 90% After Disappointing Phase 3 Trial Results, Investor Lawsuit Filed
MLTX
Legal Proceedings
Demand Weakening
Profit Warning
- MoonLake Immunotherapeutics (MLTX) experienced a nearly 90% stock price drop on the trading day following the release of disappointing Phase 3 trial results for its sole drug candidate, sonelokimab (SLK), on September 28, 2025.
- A securities fraud class action lawsuit has been filed against MoonLake, alleging the company made materially false and misleading statements about SLK's clinical prospects and exaggerated its benefits over competitors.
- The lawsuit claims MoonLake failed to disclose that SLK's distinct Nanobody structure would not provide superior clinical benefit over the competitor drug, BIMZELX, despite the company touting its molecular advantages.
- The Week 16 results from the VELA Phase 3 trials showed that one trial, VELA-2, failed to meet its primary endpoint, and the efficacy results from the other trial were substantially lower than those previously achieved by BIMZELX.
Nov 21, 2025, 7:52 PM
MoonLake Immunotherapeutics Faces Securities Class Action After Disastrous Phase 3 Trial Results
MLTX
Legal Proceedings
Profit Warning
- A securities class action has been filed against MoonLake Immunotherapeutics (MLTX) following disastrous Phase 3 trial results for its sole product candidate, sonelokimab (SLK), an anticipated treatment for skin disease.
- On September 29, 2025, MoonLake investors saw their share price crater $55.75, or about 90%, after the announcement of the trial results.
- The lawsuit alleges that MoonLake misled investors about SLK’s trial design and efficacy data, specifically concerning the purported superior clinical benefits of its Nanobody structure compared to traditional monoclonal antibodies.
- The Class Period for the lawsuit is March 10, 2024 – September 29, 2025, with a Lead Plaintiff Deadline of December 15, 2025.
Nov 19, 2025, 9:54 PM
MoonLake Immunotherapeutics Faces Securities Class Action After Disastrous Trial Results
MLTX
Legal Proceedings
Demand Weakening
Profit Warning
- MoonLake Immunotherapeutics (MLTX) is facing a securities class action lawsuit initiated by Hagens Berman after its only product candidate, sonelokimab (SLK), reported disastrous Phase 3 trial results for hidradenitis suppurativa (HS).
- Following the announcement, MoonLake's share price cratered $55.75, or approximately 90%, on September 29, 2025.
- The lawsuit alleges that MoonLake misled investors about SLK's trial design and efficacy data, specifically regarding its purported advantages and superior clinical benefit over a competitor's FDA-approved product, BIMZELX.
- The Class Period for the lawsuit is from March 10, 2024, to September 29, 2025, with a Lead Plaintiff Deadline of December 15, 2025.
Nov 18, 2025, 7:05 PM
MoonLake Immunotherapeutics Faces Securities Class Action
MLTX
Legal Proceedings
Product Launch
- MoonLake Immunotherapeutics (MLTX) is facing a securities class action lawsuit following disastrous Phase 3 trial results for its sole product candidate, sonelokimab (SLK), announced on September 28, 2025.
- The announcement caused MoonLake's share price to crater $55.75, or approximately 90%, on September 29, 2025.
- The lawsuit alleges that MoonLake misled investors about SLK's trial design and efficacy data, particularly regarding its purported advantages over a competitor's product, BIMZELX.
- The class period for the lawsuit is from March 10, 2024, to September 29, 2025, with a lead plaintiff deadline of December 15, 2025.
Nov 17, 2025, 7:24 PM
MoonLake Immunotherapeutics Faces Securities Class Action
MLTX
Legal Proceedings
Product Launch
- MoonLake Immunotherapeutics (MLTX) is facing a securities class action lawsuit, Bridgewood v. MoonLake Immunotherapeutics, et al., following the announcement of disastrous Phase 3 trial results for its only product candidate, sonelokimab (SLK).
- On September 29, 2025, MoonLake investors saw their shares crater $55.75, or about 90%, due to the trial results.
- The lawsuit alleges that MoonLake misled investors about SLK's trial design and efficacy data, specifically regarding its purported advantages over a competitor's FDA-approved product, BIMZELX.
- The class period for the litigation is from March 10, 2024, to September 29, 2025, with a lead plaintiff deadline of December 15, 2025.
Nov 12, 2025, 9:26 PM
Quarterly earnings call transcripts for MoonLake Immunotherapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more
Let Fintool AI Agent track MoonLake Immunotherapeutics's earnings for you
Get instant analysis when filings drop